Skip to main content

Table 1 The basic characteristics of the included study

From: Assessment of the risks of a myasthenic crisis after thymectomy in patients with myasthenia gravis: a systematic review and meta-analysis of 25 studies

Source Year Study year Study design No. of patients No. of myasthenic crisis cases Age at thymectomy
(mean) Age, years
Gender Male/women Study region Non-thymomatous/thymoma Significant risk factors NOS score
Kato 2019 2000–2015 retrospective cohort study 90 14 median (range) 51.5 (41.3–64.0) 41/46 Japan 33/57 (15) 8
Xue 2017 2005–2014 case-control studies 127 13 NA 68/59 china 127 (3),(10) 8
Zou 2016 2007.06–2013.12 retrospective cohort study 541 67 26.4 ± 11.7/27.06 ± 13.5 256/285 china NA (1),(4),(6),(16) 6
Ando 2015 2000.01–2013.12 case-control studies 55 10 median (range) 55 (13–79) 25/30 Japan 30/25 (1),(17) 7
Lee 2015 2007.10–2012.03 case-control studies 146 10 T/C 25.0 (15.5–48.0)/35.0 (27.0–46.0) NA Korea 105/41 (12),(18) 8
Li 2018 2000.01–2013.03 case-control studies 176 51 46.6 ± 11.7 90/83 China 0/173 (2),(19) 9
Yu 2014 1997.03–2012.03 retrospective cohort study 178 58 38.4 ± 13.2 95/83 China 69/109 (1),(2),(8) 8
Choi 2014 1996.01–2009.12 retrospective cohort study 49 12 50.3 ± 12.4 23/25 Korea 0/49 (12) 6
Leuzzi 2014 1995.01–2011.12 case-control studies 177 22 45.8 ± 16.8 107/70 Italy 53/124 (1),(3),(4),(14) 9
Nam 2011 1997.01–2007.12 retrospective cohort study 68 20 age at onset 43.6 ± 13.9 NA Japan 28/38 (1) 9
Chu 2011 1990–2009 case-control studies 243 44 31.5 ± 15.7 124/119 China 175/68 (3),(5),(13) 5
Liu 2006 1990.01–2006.01 case-control studies 176 36 31 ± 14 74/102 China 122/54 (1),(2),(6),(24) 9
Li 2016 1970.05–2011.05 case-control studies 306 49 31.54 ± 16.37 155/151 China NA (1),(2),(5) 8
Qian 2016 2002.02–2015.06 case-control studies 86 16 median (range)47 (25–71) 37/49 China 40/46 (1),(2),(3) 8
Li 2017 2008.01 ~ 2015.01 case-control studies 63 12 median (range)37 (10–76) 25/38 China 41/22 (3),(8),(9),(10) 7
Liu 2014 2011.01–2014.02 case-control studies 102 42 T/C 46.7 ± 10.11/39.6 ± 6.41 45/57 China 36/66 (3),(5),(11),(12),(20) 6
Niu 2013 2002.07–2012.07 case-control studies 134 28 age at onset 35 (1–82) 66/68 China 69/65 (3) 6
Ma 2011 1995.07–2009.12 case-control studies 84 24 median (range)42.67 (16—68) 35/49 China 21/63 (1),(3),(8),(11) 6
Zhang 2015 2008.06–2014.06 case-control studies 58 15 T/C 60.60 ± 6.20/60.7 ± 6.3 26/32 China 0/58 (3),(11),(21) 6
Wang 2006 NA case-control studies 126 13 median (range)38 (9–62) 54/72 China 56/70 (1),(3),(7),(22) 5
Chen 2007 2002.07–2005.12 case-control studies 101 29 33.2 ± 14.67 43/58 China 33/68 (1),(3),(4),(13),(23) 8
Ge 2019 2008.01–2018.01 retrospective cohort study 47 14 40.1 ± 16.7 22/25 China 24/23 (11),(13) 6
Li 2014 2008.01–2013.06 case-control studies 198 32 NA NA China 135/63 (1),(3),(5),(6) 5
Kanai 2017 2002.01–2014.12 case-control studies 275 17 T/C:45.8 ± 16.1/49.2 ± 15.5 106/169 Japan 145/130 (2),(12),(14) 9
Watanabe 2004 1985.01–2002.12 retrospective cohort study 122 44 44 ± 17 30/92 Japan 93/29 (2),(7),(9) 6
  1. MG myasthenia gravis;AchR-Ab anti-acetylcholine receptor antibody; POA preoperative anxiety
  2. (1) preoperative MC history (2) preoperative bulbar symptom (3) preoperative Osserman stages (4) postoperative lung infection (5) thymoma (6) preoperative dosage of pyridostigmine bromide (7) preoperative serum AchR-Ab level (nm/L) (8) operation time (9) intraoperative blood loss>1000 ml (10) WHO classification (11) mode of operation (12) preoperative lung function (13) major postoperative complications (14) disease duration before thymectomy (15) Masaoka stage (16) POA (17) unstable MG (18) decremental response of orbicularis oculi (19) incomplete resection (20) general anaesthesia (21) Postoperative medication (22) Potential MC (23) age (24) preoperative lung infection